Loading organizations...
Alumis is a clinical-stage biopharmaceutical company based in South San Francisco, California, that develops targeted oral therapies for immune-mediated diseases using a precision data analytics platform. The enterprise focuses on replacing broad immunosuppression with highly selective treatments, advancing a late-stage clinical pipeline that includes the TYK2 inhibitor envudeucitinib for plaque psoriasis and systemic lupus erythematosus. Operating with a team of 1 to 50 employees, the biotechnology firm secured a $259 million Series C financing round before raising an additional $210 million through its 2024 initial public offering on the NASDAQ. The clinical development programs are currently backed by prominent institutional investors including Foresite Capital, Matrix Capital Management, and Cormorant Asset Management. The company was founded in 2021 as Esker Therapeutics under the leadership of Chief Executive Officer Martin Babler, and was originally incubated by Foresite Labs.
Alumis has raised $330.0M across 2 funding rounds.
Alumis has raised $330.0M in total across 2 funding rounds.
Alumis has raised $330.0M across 2 funding rounds. Most recently, it raised $260.0M Series C in March 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2024 | $260M Series C | Foresite Capital, Srinivas Akkaraju | ARCH Venture Partners, Atlas Venture, Deerfield Management, F Prime Capital, The Column Group, VenBio Partners, Ally Bridge Group, Ayurmaya, Cormorant Asset Management, HBM Healthcare Investments, Lilly Asia Ventures, Nextech, Omega Funds, Piper Heartland Healthcare Capital, SR ONE | Announced |
| May 1, 2021 | $70M Series A | Foresite Capital | ARCH Venture Partners, Atlas Venture, Deerfield Management, F Prime Capital, The Column Group | Announced |
# Alumis: Correcting the Premise
Alumis is not a technology company—it is a biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases.[2] While the company employs advanced technology in its R&D process, its core business is drug development and therapeutic innovation, not technology product development.
Alumis is a clinical-stage biopharmaceutical company advancing a late-stage portfolio of next-generation targeted therapies to treat immune-mediated diseases.[2] The company's mission is to transform treatment for immune-mediated diseases and empower people to reimagine their lives.[2]
Alumis specializes in creating targeted therapies for autoimmune conditions including rheumatoid arthritis, lupus, and inflammatory bowel disease.[3] Rather than building software or technology products, the company solves the problem of inadequate treatment options for patients with immune dysfunction by developing precision-targeted drugs designed to improve health outcomes and enhance therapy precision.
Alumis distinguishes itself through its precision approach to R&D, which sets it apart in the competitive biopharmaceutical landscape:
Alumis operates within the broader trend of precision medicine, where treatments are increasingly tailored to individual patient genetics and disease biology rather than using one-size-fits-all approaches. The company's emphasis on leveraging genetic and translational insights reflects the industry-wide shift toward data-driven drug development. This approach addresses a critical market need: many patients with autoimmune diseases lack effective treatment options or experience inadequate responses to existing therapies.
As a late-stage clinical company, Alumis is positioned to potentially bring new therapeutic options to market for patients with significant unmet medical needs in autoimmune disease treatment. The convergence of advanced genomic sequencing, computational biology, and clinical data analytics—the foundation of Alumis's approach—represents a durable competitive advantage in drug development. Success will depend on clinical trial outcomes and regulatory approval timelines for its pipeline candidates.
Alumis has raised $330.0M in total across 2 funding rounds.
Alumis's investors include Foresite Capital, Srinivas Akkaraju, ARCH Venture Partners, Atlas Venture, Deerfield Management, F-Prime Capital Partners, The Column Group, venBio, Ally Bridge Group, AyurMaya, Cormorant Asset Management, HBM Healthcare Investments.
